We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (BOS2)

This study has been terminated.
(Low or poor accrual)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01508000
First Posted: January 11, 2012
Last Update Posted: October 12, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Amgen
Roche Pharma AG
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2016
  Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)